Drug Discovery and Drug Development

This is a preview of subscription content, log in via an institution to check access.

Access this book

Subscribe and save

Springer+ Basic €32.70 /Month

Buy Now

eBook EUR 106.99

Price includes VAT (France)

Softcover Book EUR 137.14

Price includes VAT (France)

Hardcover Book EUR 137.14

Price includes VAT (France)

Tax calculation will be finalised at checkout

Other ways to access

About this book

Over the years, India has attained a prominent global position in the manufacture of Generic Drugs. This success can be attributed to its synthetic organic chemistry and chemical engineering strengths, nurtured by the timely policies of the Government of India. However, breakthrough successes in New Drug Discovery have remained elusive, despite the brilliant and sustained efforts of many Indian researchers and Pharma establishments. The Indian National Science Academy thought it appropriate to document India’s New Drug Discovery Research (NDDR) journey to date. Gathering contributions from prominent researchers in the Indian Pharma Industry and Academia, this book highlights their efforts, achievements, and the status quo of Indian NDDR.

Similar content being viewed by others

Historical Perspective of Drug Discovery and Development

Chapter © 2021

Discovery and Development of Novel Drugs

Chapter © 2017

Drug Discovery

Chapter © 2017

Keywords

Table of contents (13 chapters)

Front Matter

Pages i-xiii

Traditional Medical System (TMS) for Sustainable Healthcare in India

Modern Drug Discovery and Development for TB: The India Narrative

Pages 37-61

Indian Discovery Effort in the Quest of Novel Antibiotics

Pages 63-95

New Drug Discovery and Development in India to Counter Malaria

Pages 97-122

Modern Drug Discovery and Development in the Area of Leishmaniasis

Pages 123-158

Introduction to Diabetes and Prevalence in India

Pages 159-163

Type 2 Diabetes Mellitus: Marketed Drugs and Mechanisms

Pages 165-177

Anti-diabetes Research in India: Contributions from Industrial Organizations

Pages 179-212

Indian Academia Tryst with Cardio-metabolic Drug Discovery and Development

Pages 213-225

Modern Drug Discovery and Development in the Area of Cancer: Indian Context

Pages 227-253

Biopharmaceutical Development in India: Recommendations on Collaboration and Innovation to Enable Affordable Healthcare

Pages 255-281

Regulatory Requirements and Quality Standards in India’s Clinical Trials Journey

Pages 283-302

New Drug Discovery and Development: Indian Pharmaceutical Industry

Pages 303-376

Editors and Affiliations

NCR Biotech Science Cluster, Translational Health Science and Technology Institute, Faridabad, India

About the editor

Dr Madhu Dikshit, a highly respected researcher and former Director of the CSIR-Central Drug Research Institute, Lucknow, India, has made significant contributions to the general area of Molecular Pharmacology with a special interest in redox biology. Dr Dikshit’s research has impacted the area of neutrophil biology by enhancing our understanding of e.g. chemotaxis, phagocytosis, apoptosis and also differentiation. Her pioneering work has helped identify the molecular mechanisms involved in the translocation of Nitric Oxide Synthase to the phagosomal compartment and the inflammatory potential of neutrophil extracellular traps. At the CSIR-CDRI, she initiated and led the successful anti-thrombotic drug discovery program, in the context of which two new chemical entities advanced to the pre-clinical stage and one has recently received approval for Phase I clinical trials. Dr Dikshit has published more than 170 papers in peer-reviewed journals, holds eight patents and has supervised more than 30 PhD students. Presently she is the National Chair at Translational Health Sciences & Technology Institute (THSTI), Faridabad and heads its Non-Communicable Disease Program.

Bibliographic Information